Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Interleukin 23 inhibitors for psoriasis: not just another number

Major advances have been made in the past 30 years in elucidating the pathogenesis of psoriasis, including the identification of T-helper 17 (Th17) lymphocytes as key players in psoriatic inflammation. Th17 lymphocytes are pathogenetic mainly through the release of their effector cytokine, interleukin 17.1 Although Th17 cells infiltrating psoriatic plaques release other pathogenetic cytokines, such as interleukin 22, the clinical development of several effective interleukin 17 inhibitors—including secukinumab and ixekizumab, which have been licensed for use in moderate-to-severe psoriasis—provided an enlightening demonstration of this model of pathogenesis.